Mantle Cell Lymphoma
Lugano, Switzerland –
CHICAGO – Bendamustine plus rituximab may have some advantages for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle cell...
Umbralisib, a second-generation PI3K inhibitor, appears to have a better safety profile than the first-in-class agent idelalisib.
From the Journals
Liposomes might be able to boost efficacy and reduce side effects of bortezomib.
High-risk patients with mantle cell lymphoma who have a matched related donor have a better chance for survival if they do not delay allogeneic...
The peripheral blood absolute lymphocyte-to-monocyte ratio (ALC/AMC) was prognostic for overall survival in mantle cell lymphoma patients who have...
How might a new trial, ZUMA-2, affect mantle cell lymphoma treatment once completed?
Combined idelalisib, lenalidomide, and rituximab proved excessively toxic for the treatment of relapsed and refractory mantle cell and follicular...
NEW YORK – Maintenance therapy puts off life-disrupting autologous stem cell transplantation, perhaps for what may be several years, but relapse...
MAGNIFY is actively recruiting patients.
Up to two-thirds of the mutations that drive human cancers may be due to DNA replication errors in normally dividing stem cells, not by inherited...